Wall Street Zen upgraded shares of Seaport Therapeutics (NASDAQ:SPTX – Free Report) to a hold rating in a research note released on Saturday morning.
Seaport Therapeutics Stock Performance
NASDAQ SPTX opened at $16.05 on Friday. Seaport Therapeutics has a 52-week low of $14.85 and a 52-week high of $23.00.
Insider Activity at Seaport Therapeutics
In other Seaport Therapeutics news, major shareholder Arch Venture Partners Xii, Llc acquired 1,100,000 shares of Seaport Therapeutics stock in a transaction dated Monday, May 4th. The stock was bought at an average cost of $18.00 per share, with a total value of $19,800,000.00. Following the acquisition, the insider owned 6,294,951 shares of the company’s stock, valued at approximately $113,309,118. The trade was a 21.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Featured Stories
- Five stocks we like better than Seaport Therapeutics
- Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due
- Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches
- Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money
- Water Infrastructure: Why This Boring Sector Could Get Exciting
Receive News & Ratings for Seaport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seaport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
